3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Specimen Handling
278
Magnetic Resonance Spectroscopy
233
pembrolizumab
227
Carboplatin
187
Cisplatin
153
Biopsy
148
Cyclophosphamide
143
Paclitaxel
133
Nivolumab
122
Gemcitabine
113
Bevacizumab
104
Radiotherapy
92
Dexamethasone
86
Pemetrexed
83
fludarabine
77
Fluorouracil
76
Docetaxel
75
Doxorubicin
74
atezolizumab
71
Radiation
71
Leucovorin
70
Rituximab
67
Oxaliplatin
66
venetoclax
61
durvalumab
61
Prednisone
60
Vincristine
56
Cetuximab
56
Lenalidomide
54
Etoposide
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
tucatinib
×
30 days
×
Clear all
NCT05253651
2026-06-04
MOUNTAINEER-03
Seagen Inc.
Phase 3
Recruiting
400 enrolled
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT06686394
2026-05-22
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
81 enrolled